Opioid-sparing effect of Nefopam for acute postoperative pain in patients undergoing laparoscopic bariatric surgery

Phase 4

• Conditions: Morbid obesity; Morbid obesity, Bariatric surgery, Nefopam

• Registration Number: TCTR20211001001
• Lead Sponsor: Faculty of Medicine Siriraj Hospital Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-01
• Study Completion: 2023-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Age 18-70 yrs
2. Scheduled for laparoscopic bariatric surgery
3. Be able to control Patient-controlled analgesia pump
4. Understand Thai consent received

Exclusion Criteria

1. Contraindicated for Nefopam use
2. Known history of cardiac disease : CAD, CHF, arrhythmia
3. CrCl < 40ml/min
4. Chronic liver disease Child Pugh class B,C
5. Hypersensitivity to nefopam, fentanyl, bupivacaine
6. Chronic opioid user

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
efopam can decrease fentanyl consumption postoperatively in patients undergoing laparoscopic bariatric surgery at 6 hours after operation finished Numeric Rating Scale Score

Secondary Outcome Measures

Name	Time	Method
efopam can decrease fentanyl consumption at 24 hours postoperatively in patients undergoing laparoscopic bariatric surgery at 24 hours after operation finished Numeric Rating Scale Score